These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 17652604)

  • 1. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.
    Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW
    J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
    Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.
    Isingrini E; Guinaudie C; C Perret L; Rainer Q; Moquin L; Gratton A; Giros B
    Sci Rep; 2017 Sep; 7(1):12432. PubMed ID: 28963508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
    Guillot TS; Shepherd KR; Richardson JR; Wang MZ; Li Y; Emson PC; Miller GW
    J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
    Colebrooke RE; Humby T; Lynch PJ; McGowan DP; Xia J; Emson PC
    Eur J Neurosci; 2006 Nov; 24(9):2622-30. PubMed ID: 17100850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
    Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
    Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
    Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O
    J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
    Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW
    Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Jourdain S; Morissette M; Morin N; Di Paolo T
    J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
    Lohr KM; Stout KA; Dunn AR; Wang M; Salahpour A; Guillot TS; Miller GW
    ACS Chem Neurosci; 2015 May; 6(5):790-9. PubMed ID: 25746685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vesicular monoamine transporter 2 mediates fear behavior in mice.
    Branco RC; Burkett JP; Black CA; Winokur E; Ellsworth W; Dhamsania RK; Lohr KM; Schroeder JP; Weinshenker D; Jovanovic T; Miller GW
    Genes Brain Behav; 2020 Jun; 19(5):e12634. PubMed ID: 31898856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity.
    Taylor TN; Caudle WM; Shepherd KR; Noorian A; Jackson CR; Iuvone PM; Weinshenker D; Greene JG; Miller GW
    J Neurosci; 2009 Jun; 29(25):8103-13. PubMed ID: 19553450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
    Kariya S; Takahashi N; Hirano M; Ueno S
    J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.
    Taylor TN; Caudle WM; Miller GW
    Parkinsons Dis; 2011 Feb; 2011():124165. PubMed ID: 21403896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
    Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.